Contemporary HIV Management: A Collection of Quick Case-Based Commentaries
Source: Quick Cases: Key Concepts in the Contemporary Management of HIV

Module

This collection of case-based expert commentaries reinforces core concepts relevant to the contemporary management of HIV. Various experts provide practical perspectives on recent treatment advances and everyday clinical challenges.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply best practices when selecting first-line antiretroviral regimens for HIV-infected patients
  • Integrate treatment modification strategies when appropriate for patients already receiving antiretroviral therapy
  • Provide individualized care for key populations of HIV-infected patients, according to factors such as sex, race, and age
  • Provide insightful counsel to patients and colleagues regarding antiretroviral strategies in development

Topics covered include:

  • Therapies and Strategies in Advanced Clinical Development
  • Management of Aging Patients With HIV
  • Best Practices for ART Management and Optimizing Outcomes in Persons of Color
  • Management of HIV in Women
  • To Boost or Not to Boost: Advantages and Disadvantages of Boosted ART
  • New Data From CROI 2017
  • New Data From IAS 2017
 

Faculty

  • Eric S. Daar
    MD
    Charles B. Hicks
    MD
    Lisa Hightow-Weidman
    MD, MPH
    Daniel R. Kuritzkes
    MD
    Paul E. Sax
    MD
    Kathleen E. Squires
    MD
    David A. Wohl
    MD

Credit Information

  • Release Date:
    November 10, 2017
  • Expiration Date:
    November 09, 2018
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit
  • Registered Nurses:
    1.0 Nursing contact hour
  • Pharmacists:
    1.0 contact hour (0.1 CEUs)

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Eric S. Daar, MD


Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, Teva, and ViiV and funds for research support from Gilead Sciences, Merck, and ViiV.
 

Charles B. Hicks, MD


Professor of Clinical Medicine
Director,
 Owen Clinic
University of California, San Diego
San Diego, California

Charles B. Hicks, MD, has disclosed that he has received consulting fees from Janssen, Merck, and ViiV and royalties from UpToDate, Inc.
 

Lisa Hightow-Weidman, MD, MPH


Associate Professor
Division of Infectious Diseases
Department of Medicine
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina

Lisa Hightow-Weidman, MD, MPH, has no real or apparent conflicts of interest to report.
 

Daniel R. Kuritzkes, MD


Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV and funds for research support from Abbott, Gilead Sciences, and Merck.
 

Paul E. Sax, MD


Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul E. Sax, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen, and Merck and funds for research support from Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline/ViiV.
 

Kathleen E. Squires, MD


W. Paul and Ida H. Havens Professor of Infectious Diseases
Director,
Division of Infectious Diseases
Sidney Kimmel Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania

Kathleen E. Squires, MD, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from Gilead Sciences.
 

David A. Wohl, MD


Professor of Medicine
School of Medicine
Site Leader,  AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director, HIV Services
North Carolina Department of Correction
Raleigh, North Carolina

David A. Wohl, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, and ViiV and funds for research support from Gilead Sciences.
 

Staff

Jennifer M. Blanchette, PhD


Managing Editor

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
 

Ryan P. Topping, PhD


Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
 

Megan Cartwright, PhD


Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
 

Megan K. Murphy, PhD


Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Annenberg Center for Health Sciences at Eisenhower planners and managers, Charles E. Willis, MBA, Director of Continuing Education receives consulting fees from Pfizer, Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians, registered nurses, physician assistants, pharmacists, and other healthcare professionals who provide care for HIV-infected patients.


Goal

The goal of this activity is to improve participants’ competence in providing optimal care for HIV-infected patients through the appropriate use of contemporary antiretroviral regimens.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply best practices when selecting first-line antiretroviral regimens for HIV-infected patients
  • Integrate treatment modification strategies when appropriate for patients already receiving antiretroviral therapy
  • Provide individualized care for key populations of HIV-infected patients, according to factors such as sex, race, and age
  • Provide insightful counsel to patients and colleagues regarding antiretroviral strategies in development
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

 

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-17-097-H01-P. This program is designated for up to 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit.

Type of Activity Application

 

Commercial Support


This program is supported by an educational grant from ViiV Healthcare.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 10, 2017, through November 09, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.